![Magnus Nylén](data:image/svg+xml,<svg xmlns="http://www.w3.org/2000/svg" width="16" height="16" fill="%231b1b1b" class="bi bi-person-fill" viewBox="0 0 16 16"><path d="M3 14s-1 0-1-1 1-4 6-4 6 3 6 4-1 1-1 1zm5-6a3 3 0 1 0 0-6 3 3 0 0 0 0 6"/></svg>)
Magnus Nylén
Direktor/Vorstandsmitglied bei
SELECTIMMUNE PHARMA AB (PUBL)
Profil
Magnus Nylén is currently Director at Hamlet BioPharma AB starting in 2025.
Mr. Nylén is also Director at SelectImmune Pharma AB since 2022.
Additionally, Mr. Nylén has been Owner at Partner Fondkommission AB since 2013.
Mr. Nylén completed undergraduate education at Boston University.
Aktive Positionen von Magnus Nylén
| Unternehmen | Position | Beginn |
|---|---|---|
| SELECTIMMUNE PHARMA AB (PUBL) | Direktor/Vorstandsmitglied | 23.11.2022 |
| HAMLET PHARMA AB (PUBL) | Direktor/Vorstandsmitglied | 11.03.2025 |
Partner Fondkommission AB
 Partner Fondkommission AB Investment ManagersFinance Offers financial advisory | Corporate Officer/Principal | 01.01.2013 |
Ausbildung von Magnus Nylén
Erfahrungen
Besetzte Positionen
Aktive
Inaktive
Börsennotierte Unternehmen
Private Unternehmen
Beziehungen
6
Beziehungen ersten Grades
4
Unternehmen ersten Grades
Herr
Frau
Aufsichtsräte
Führungskräfte
Unternehmensverbindungen
| Private Unternehmen | 4 |
|---|---|
Boston University
 Boston University Other Consumer ServicesConsumer Services Functions as a College/University | Consumer Services |
Partner Fondkommission AB
Partner Fondkommission AB Investment ManagersFinance Offers financial advisory | Finance |
Hamlet BioPharma AB
 Hamlet BioPharma AB Pharmaceuticals: MajorHealth Technology Engages in the research and development of pharmaceutical products specifically for cancer patients | Health Technology |
SelectImmune Pharma AB
 SelectImmune Pharma AB Pharmaceuticals: MajorHealth Technology Operates as a pharmaceutical company which develops and manufactures immune enhancers to complement antibiotics | Health Technology |
